TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.
The randomized, double-blind, placebo-controlled Phase II study will evaluate the safety and efficacy of TG-C in patients with chronic degenerative joint disease (DJD) of the knee. Patients will receive an intra-articular injection of either TG-C or placebo to the damaged joint area with primary and secondary endpoints involving evidence of symptomatic improvement and cartilage regeneration, respectively. This multi-center study will be conducted at hospitals and clinical research centers across the United States specializing in orthopedic research and is expected to include 100 patients. In conjunction with these efforts, TissueGene's licensing partner, Kolon Life Science, Inc. (KOSDAQ: 102940) anticipates the initiation of a Phase IIb single-dose study for TG-C in Korea by 3Q 2011, having previously received regulatory allowance by the Korean FDA to proceed.
"We are pleased to have reached another significant milestone with the start of our U.S. Phase II study of TG-C," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene. "We believe that TG-C has the potential to become the first noninvasive treatment for osteoarthritis by regenerating cartilage through a simple injection into the knee."
Epilepsy drug may alleviate joint degeneration associated with osteoarthritis